Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT ID: NCT00056654

Last Updated: 2008-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Study Completion Date

2004-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate administered once every 26 weeks for 1 year, will lower testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma. This study will also evaluate the pharmacokinetic profile of the 45 mg formulation and assess the safety of this formulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Neoplasms

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Leuprolide Prostatic Neoplasms Testosterone Prostate-specific Antigen Pharmacokinetics luprolide acetate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Leuprolide acetate

Intervention Type DRUG

45 mg Intramuscular injection 6 month depot formulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Leuprolide acetate

45 mg Intramuscular injection 6 month depot formulation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological diagnosis of prostate cancer
* Need for androgen deprivation treatment for 1 year
* Serum testosterone level ≥ 150 ng/dL
* Life expectancy of at least 18 months
* ECOG Performance status grades 0,1 or 2

Exclusion Criteria

* Hypersensitivity to leuprolide acetate or polylactic acid
* History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
* History of hypogonadism
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abbott

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urology Centers of Alabama

Homewood, Alabama, United States

Site Status

Medical Affiliated Research Center

Huntsville, Alabama, United States

Site Status

Alaska Clinical Research Center, LLC

Anchorage, Alaska, United States

Site Status

Arkansas Urology

Little Rock, Arkansas, United States

Site Status

Pacific Clinical Center

Encino, California, United States

Site Status

Los Angeles Clinical Research Center

Encino, California, United States

Site Status

Urology Associates of Central California

Fresno, California, United States

Site Status

Center for Urologic Research

La Mesa, California, United States

Site Status

South Orange County Medical Research Center

Laguna Woods, California, United States

Site Status

San Diego Uro-Research

San Diego, California, United States

Site Status

Western Clinical Research

Torrance, California, United States

Site Status

Urology Research Options

Aurora, Colorado, United States

Site Status

Connecticut Clinical Research Center

Waterbury, Connecticut, United States

Site Status

South Florida Medical Research

Aventura, Florida, United States

Site Status

Atlantic Urological Associates

Daytona Beach, Florida, United States

Site Status

UroSearch

Inverness, Florida, United States

Site Status

Advanced Research Institute

New Port Richey, Florida, United States

Site Status

Atlantic Urological Associates

New Smyrna Beach, Florida, United States

Site Status

UroSearch

Ocala, Florida, United States

Site Status

Florida Foundation for Healthcare Research

Ocala, Florida, United States

Site Status

Atlantic Urological Associates

Orange City, Florida, United States

Site Status

Atlantic Urological Associates

Saint Augustine, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Georgia Urology, PA

Atlanta, Georgia, United States

Site Status

West Side Veteran Administration Medical Center

Chicago, Illinois, United States

Site Status

Kankakee Urological Associates

Kankakee, Illinois, United States

Site Status

Specialty Care Research

Peoria, Illinois, United States

Site Status

Welborn Clinic East

Evansville, Indiana, United States

Site Status

Northeast Indiana Research

Fort Wayne, Indiana, United States

Site Status

Urology of Indiana, LLC

Indianapolis, Indiana, United States

Site Status

Urological Associates, PC

Davenport, Iowa, United States

Site Status

206 Research Associates

Greenbelt, Maryland, United States

Site Status

Lawrenceville Urology

Saint Joseph, Michigan, United States

Site Status

Kansas City Urology Care

Kansas City, Missouri, United States

Site Status

Saint Louis Urological Surgeons, Inc

St Louis, Missouri, United States

Site Status

Sheldon J. Freedman, MD, LTD

Las Vegas, Nevada, United States

Site Status

Nevada Urology Associates

Reno, Nevada, United States

Site Status

Urological Surgical Associates

Edison, New Jersey, United States

Site Status

Lawrenceville Urology

Lawrenceville, New Jersey, United States

Site Status

Associated Urologic Specialists, PA

Marlton, New Jersey, United States

Site Status

Suffolk Urology Associates

Bay Shore, New York, United States

Site Status

Urological Surgeons of Long Island

Garden City, New York, United States

Site Status

Hudson Valley Urology

Poughkeepsie, New York, United States

Site Status

Center for Urologic Research of Western New York

Williamsville, New York, United States

Site Status

Northeast Urology Research

Concord, North Carolina, United States

Site Status

The Urology Group

Cincinnati, Ohio, United States

Site Status

University Urological Research Institute

Providence, Rhode Island, United States

Site Status

Grand Strand Urology

Myrtle Beach, South Carolina, United States

Site Status

Vanderbilt Medical Center Dept of Urologic Surgery

Nashville, Tennessee, United States

Site Status

Urology Specialists & Associates

Dallas, Texas, United States

Site Status

Urology Associates of North Texas

Fort Worth, Texas, United States

Site Status

Urology San Antonio Research

San Antonio, Texas, United States

Site Status

Salt Lake Research

Salt Lake City, Utah, United States

Site Status

Devine-Tidewater Urology

Virginia Beach, Virginia, United States

Site Status

Madigan Army Medical Center

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C02-008

Identifier Type: -

Identifier Source: org_study_id